Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Amanda Helena TejadaMolecular Oncology Research Center, Barretos Cancer Hospital, Antenor Duarte Villela, 1331, Barretos 14784-400, SP, Brazil.ORCID 0009-0009-5494-0894
Samuel José SantosLaboratório de Sínteses Orgânicas, Instituto de Química, Universidade Federal do Rio Grande do Sul, Porto Alegre 90010-150, RS, Brazil.
Gabriel Tofolli LoboMolecular Oncology Research Center, Barretos Cancer Hospital, Antenor Duarte Villela, 1331, Barretos 14784-400, SP, Brazil.
Abu-Bakr Adetayo AriwoolaMolecular Oncology Research Center, Barretos Cancer Hospital, Antenor Duarte Villela, 1331, Barretos 14784-400, SP, Brazil.ORCID 0000-0002-1535-4819
Aryel José Alves BezerraMolecular Oncology Research Center, Barretos Cancer Hospital, Antenor Duarte Villela, 1331, Barretos 14784-400, SP, Brazil.
Giulia Rodrigues StringhettaMolecular Oncology Research Center, Barretos Cancer Hospital, Antenor Duarte Villela, 1331, Barretos 14784-400, SP, Brazil.ORCID 0000-0002-5217-7823
Izabela Natalia Faria GomesMolecular Oncology Research Center, Barretos Cancer Hospital, Antenor Duarte Villela, 1331, Barretos 14784-400, SP, Brazil.ORCID 0000-0003-0551-138X
Luciane Sussuchi da SilvaMolecular Oncology Research Center, Barretos Cancer Hospital, Antenor Duarte Villela, 1331, Barretos 14784-400, SP, Brazil.ORCID 0000-0002-7470-4655
Rui Manuel V ReisMolecular Oncology Research Center, Barretos Cancer Hospital, Antenor Duarte Villela, 1331, Barretos 14784-400, SP, Brazil.ORCID 0000-0002-9639-7940
Daniel D'Almeida PretoClinical Oncology Department, Barretos Cancer Hospital, Antenor Duarte Villela, 1331, Barretos 14784-400, SP, Brazil.ORCID 0000-0002-6561-7322
Dennis RussowskyLaboratório de Sínteses Orgânicas, Instituto de Química, Universidade Federal do Rio Grande do Sul, Porto Alegre 90010-150, RS, Brazil.ORCID 0000-0001-5968-9760
Renato José Silva-OliveiraMolecular Oncology Research Center, Barretos Cancer Hospital, Antenor Duarte Villela, 1331, Barretos 14784-400, SP, Brazil.ORCID 0000-0001-6500-4190
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Hybrid Dihydropyrimidinones Targeting AKT Signaling: Antitumor Activity in Hormone-Dependent 2D and 3D Cancer Models. · full record | OpenQuestion